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Introduction: The tyrosine kinase KIT has variable expression in
small-cell lung cancer (SCLC) and may be a prognostic factor.
Imatinib targets KIT expression, providing rationale for studying its
role in combination with chemotherapy in SCLC in a multicenter
phase II trial.
Methods: Patients with untreated extensive-stage SCLC received
carboplatin area under the concentration-time curve of 4 on day 1;
irinotecan 60 mg/m2 on days 1, 8, and 15; and imatinib 600 mg/day.
Treatment cycles were 28 days. Patients remained on imatinib until
progressive disease or significant toxicity.
Results: Between September 2002 and May 2004, 68 patients were
enrolled in this multicenter trial. Median age was 60 years (range,
37–81). The objective response rate was 66% (95% confidence
interval: 54%–76%). Median progression-free survival was 5.4
months (95% CI: 4.3–6.0 months). Median overall survival was 8.4
months (95% CI: 6.3–10.5 months). Thirty-five percent of patients
were alive at 1 year. Grade 3/4 hematologic toxicity included
neutropenia (43%), anemia (16%), and thrombocytopenia (9%).
Grade 3 nonhematologic toxicity included diarrhea (19%), fatigue
(24%), and nausea (26%). Forty-eight of 56 patients (86%) with
available tumor specimens had KIT expression detected. KIT ex-
pression did not appear to correlate with progression-free survival or
overall survival in a retrospective analysis.
Conclusions: Irinotecan, carboplatin, and imatinib is a safe and
generally well-tolerated regimen in patients with SCLC. However,
the addition of imatinib did not improve results from those expected
with chemotherapy alone.
Key Words: Imatinib, Small-cell lung cancer, extensive-stage, KIT,
Carboplatin, Irinotecan.
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The majority of patients with extensive-stage small-celllung cancer (ES-SCLC) will not survive beyond 2 years.1
Despite high response rates with chemotherapy, modern com-
bination regimens have not dramatically affected mortality
with median survival times averaging 8 to 10 months.2–4
Likewise, triplet combinations have not improved survival
when compared with doublet regimens, although toxicity is
increased.5,6 Newer treatment strategies incorporating novel
biologic agents are needed.
Imatinib is an oral inhibitor of several kinases including
KIT, which is variably expressed in SCLC and may be an
important target for treatment.7,8 Inhibition of KIT activation
has proven to be a successful strategy in the treatment of
gastrointestinal stromal tumors.9 The published experience
with imatinib in SCLC has been limited to date. Single-agent
studies and a small phase I experience in combination with
chemotherapy have not suggested benefit.10–12 Given the
variable expression of KIT in SCLC and the ability of
imatinib to inhibit this expression, a multicenter phase II trial
of chemotherapy and imatinib was initiated in previously
untreated patients with ES-SCLC. The platform chemother-
apy used in this study was carboplatin and irinotecan, a
generally well-tolerated and active regimen studied by our
group and others in SCLC treatment.13–16
METHODS
This multicenter phase II trial was initiated in Septem-
ber 2002. Participating centers in the trial included the Sarah
Cannon Cancer Center and selected sites from the Minnie
Pearl Cancer Research Network (Appendix). This trial was
approved by the institutional review boards of all participat-
ing institutions.
Patient Eligibility
Patients with cytologically or histologically confirmed
ES-SCLC were enrolled. Patients had measurable disease by
Response Evaluation Criteria in Solid Tumors (RECIST).17
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Other eligibility criteria included no previous systemic che-
motherapy, primary radiation, or biologic treatment; Eastern
Cooperative Oncology Group (ECOG) performance status 0
or 1; adequate organ function (defined as absolute neutrophil
count [ANC]1.5 109/L and platelet count100 109/l,
total bilirubin 3.0 mg/dl, aspartate aminotransferase
(SGOT) three times or less the institutional upper limit of
normal, and creatinine 1.6 mg/dl); absence of active brain
metastases; and age 18 years or older. Patients were excluded
if they had a previous malignancy within 3 years with the
exception of skin cancer (excluding melanoma), cervical
carcinoma in situ, in situ breast carcinoma, or early-stage
prostate cancer. Women who were pregnant or lactating were
also excluded. Patients with reproductive potential were re-
quired to use barrier contraception during treatment. All
patients were required to provide written informed consent
before study entry.
Pretreatment Evaluation
Before beginning therapy, all patients were evaluated
with routine histories, physical examinations, chemistry pro-
files, and complete blood counts. Tumor staging with com-
puted tomography scans of the chest and upper abdomen and
bone scanning was required. Computed tomography or mag-
netic resonance imaging of the head was also required. Bone
marrow biopsy was not required if ES-SCLC could be con-
firmed by other staging procedures.
Treatment Plan
At the time this study was designed, experience with
irinotecan and carboplatin in SCLC was emerging. Our center
previously studied this combination in a phase I study in
patients with refractory malignancies and determined the
regimen used for this study in previously untreated patients
with ES-SCLC.18 All patients received irinotecan 60 mg/m2
administered by intravenous (IV) infusion on days 1, 8, and
15, IV carboplatin at an area under the concentration-time
curve of 4 on day 1, and imatinib 600 mg/day orally. Irino-
tecan was infused prior to carboplatin, with each adminis-
tered over 30 to 60 minutes. The carboplatin dose was
calculated using the method described by Calvert et al.19
Treatment cycles were repeated every 28 days for four to six
cycles. After four cycles, in selected patients based on clinical
judgment, two additional cycles of treatment could be admin-
istered. Patients remaining in remission or with stable disease
after completion of four to six cycles continued imatinib
600 mg daily until tumor progression or for a maximum of 24
months, with re-evaluation at 2-month intervals.
Because imatinib is a local irritant, patients were
instructed to take this in a sitting position with a large (250
ml) glass of water. It was advised that imatinib not be
taken with grapefruit juice. If a patient had significant
gastrointestinal intolerance, the dose could be split into
twice-daily dosing.
Cytokines were not administered with the first course of
treatment. Prophylactic granulocyte colony-stimulating factor
for patients experiencing febrile neutropenia was permitted at
the discretion of the treating physician, but was not to
substitute for mandated dose reductions. Routine antiemetics
were used as premedication.
Patients were seen and examined by their physicians on
a monthly basis. After 8 weeks of treatment, patients were
evaluated for response. At restaging, repeat computed tomog-
raphy scans of all measurable lesions were performed. Based
on this evaluation, all patients were assigned a response
category. Patients who had objective response or stable dis-
ease continued to receive additional treatment. Patients with
tumor progression were removed from the study. Patients
with symptomatic bone metastases could receive concomitant
palliative radiation therapy during study treatment.
Imatinib was supplied by Novartis AG (Basel, Switzer-
land) as 100-mg capsules packaged in bottles. Medication
labels complied with federal legal requirements and were
printed in English. Bottles were stored in a safe and secure
central location and were then distributed to participating
sites. Commercially available forms of irinotecan and carbo-
platin were used.
Dose modifications were based on absolute neutrophil
and platelet counts on day 1 of each cycle. Dose adjustments
at the beginning of each cycle were not made based on nadir
blood counts. No dose adjustments were required if the ANC
was 1.5  109/l and the platelet count was 100  109/l.
If the ANC was 1.0  109/l, but 1.5  109/l or platelets
75  109/l, but 100  109/l, irinotecan and carboplatin
were reduced 25%, and imatinib was lowered to 400 mg. If
the ANC was 100  109/l or platelets 75  109/l, all
therapy was held up to 2 weeks. When counts recovered,
irinotecan and carboplatin were reduced 25% and imatinib
lowered to 400 mg. If counts did not recover within 2 weeks,
the patient came off study. Chemotherapy doses were not
increased once modified; however, imatinib could be in-
creased to 600 mg once counts recovered to the entry criteria
level. Missed doses were not made up. Dose modifications for
irinotecan and imatinib on days 8 and 15 were made accord-
ing to the same parameters. Patients requiring hospitalization
for neutropenia and fever had 25% dose reductions for irinote-
can and carboplatin, and imatinib was reduced to 400 mg.
Patients experiencing grade 3/4 nonhematologic toxic-
ity had treatment held until the toxicity resolved to less than
grade 2; chemotherapy was then resumed with 25% dose
reductions of the offending agents. Imatinib was held until
the toxicity resolved to grade 1 or lower and then resumed at
400 mg. If grade 3/4 toxicity recurred, imatinib was withheld
until toxicity resolved to grade 1 or lower and resumed at 200
mg. If grade 3/4 toxicity recurred a third time, imatinib was
discontinued. Patients experiencing any grade 4 nonhemato-
logic toxicity could be removed from the study at the discre-
tion of the treating physician.
Patients who developed grade 2 or 3 diarrhea had
irinotecan and imatinib held up to 2 weeks until the diarrhea
improved to grade 1 or lower. Both agents were resumed at
full dose.
Definition of Response
All patients were reevaluated for response by RECIST.17
All patients with major responses had confirmation of re-
sponse on repeat scans performed at 8-week intervals. Pa-
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tients with stable disease or minor responses at 8 weeks were
reevaluated at 2-month intervals as treatment continued. The
final response category assigned to these patients represented
the best response obtained during their treatment course.
Statistical Methods
This nonrandomized phase II study was designed to
assess the tumor response rate. We considered the achieve-
ment of a 70% objective response rate to be a level of efficacy
commensurate with irinotecan and carboplatin alone.13–15 A
higher response rate would be worthy of additional develop-
ment of this combination regimen. Achievement of 48
responses among a total of 68 patients would indicate a true
response rate of 70%. The  level of this design was 0.05
and the power was 0.85.
Progression-free survival (PFS) was defined as the date
of study entry until the date that tumor progression was
documented. Overall survival (OS) was measured from the
date of study entry until the date of death. Survival curves
were constructed by using the method of Kaplan and Meier.20
Comparisons of PFS and OS for various subsets of patients
based on KIT expression were accomplished by using two-
sided log-rank analysis.21 KIT expression by immunohisto-
chemistry was scored by one pathologist who was blinded to
treatment outcome. Immunohistochemistry analyses were
performed using the Pathway Anti-c-KIT (9.7) Primary An-
tibody (Ventana Medical Systems, Inc., Tucson, AZ), a
purified rabbit monoclonal antibody directed against the in-
tracellular domain of the c-KIT oncoprotein. Expression was
scored two ways: positive (1, 2, or 3) or negative (0).
Toxicity was evaluated in all patients who received at least
one dose of therapy. Toxicity was graded according to
National Cancer Institute Common Toxicity Criteria, ver-
sion 3.0.
RESULTS
Patient Characteristics
Between September 2002 and May 2004 68 patients
were enrolled by 15 participating sites in the Minnie Pearl
Cancer Research Network (Appendix). Patient characteristics
are summarized in Table 1. Patients in this trial had a median
age of 60 years; the majority had ECOG 1 performance
status.
Treatment Received
Fifty-nine patients (87%) completed the planned four
courses of irinotecan, carboplatin, and imatinib, and were
evaluated for response. Nine patients were withdrawn from
treatment before completing two courses for the following
reasons: rapid tumor progression (two patients), treatment-
related death (one patient), intercurrent illness (three pa-
tients), poor subjective response (one patient), treatment-
related toxicity (carboplatin hypersensitivity reaction, one
patient), and poor compliance (one patient). The median
number of chemotherapy cycles received was four (range,
one to six). Twenty-four patients (35%) completed six
courses of combination chemotherapy, and 26 patients (38%)
went on to receive imatinib alone for a median of 2 months
(range, 1–5).
Response to Treatment
The intent-to-treat responses of the 68 patients enrolled
in this trial are shown in Table 2. Forty-five of 68 patients
(66%, 95% confidence interval [CI]: 54%–76%) had objec-
tive responses (partial response, 42; complete response, three
including one unconfirmed complete response). An additional
eight patients (12%) had stable disease. Eight patients (12%)
had disease progression by the time of their first reevaluation
(8 weeks).
With a median follow-up of 24 months, PFS and OS for
the entire group of patients are shown in Figures 1 and 2,
respectively. The median PFS was 5.4 months (95% CI:
4.3–6.0). The median OS for the entire group was 8.4 months
(95% CI: 6.3–10.5). Thirty-five percent of patients were alive
at 1 year.
KIT expression was not a requirement for enrollment.
Tissue blocks were available for KIT analysis on 56 patients
(82%) (Table 3). Figures 3–6 compare PFS and OS in
patients by KIT expression as measured by different scoring
scales. No comparison shows statistically significant differ-
ences in PFS or OS when stratified by KIT expression.
TABLE 1. Patient Characteristics (n  68)
Characteristic Patients
Age, yr
Median 60
Range 37–81
Gender
Male 39 (57%)
Female 29 (43%)
Racial/ethnic origin
White 64 (94%)
African descent 4 (6%)
ECOG performance status
0 16 (24%)
1 52 (76%)
Previous treatment for brain metastases 1 (1%)
Location of treatment facility
Sarah Cannon Cancer Center 37 (54%)
Network sites 31 (46%)
ECOG, Eastern Cooperative Oncology Group.
TABLE 2. Response to Treatment (n  68)
Response No. (%)
Complete 3a (4)
Partial 42 (62)
Stable disease 8 (12)
Progression 8 (12)
Unassessable 7 (10)
a One unconfirmed complete response.
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Treatment-Related Toxicity
Treatment-related toxicity is summarized in Table 4. The
most common grade 3/4 toxicity during combination therapy
was neutropenia, which occurred in 43% of patients. Grade 3/4
anemia occurred in 16% of patients. Five patients (7%) required
hospitalization for treatment of neutropenia and fever. Granulo-
cyte colony-stimulating factor, granulocyte-macrophage colony-
stimulating factor, or erythropoietin agents were used in 85% of
patients at some time during treatment. There was one (1%)
treatment-related death, possibly due to hypokalemia.
FIGURE 1. Progression-free survival (PFS)
for the entire group (n  68).
FIGURE 2. Overall survival for the entire
group (n  68). CI, confidence interval; pts,
patients.
FIGURE 3. Progression-free survival (PFS)
by KIT expression: positive or negative. pt,
patient.
TABLE 3. KIT Expression Scoring (n  56)
KIT Expression No. %
Positive 48 86
Negative 8 14
0 8 14
1 9 16
2 21 38
3 18 32
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Severe nonhematologic toxicity, other than alopecia, was
relatively uncommon. Nineteen percent of patients had grade 3
diarrhea (0, grade 4) and 24% had grade 3 fatigue/weakness (0,
grade 4). Twenty-six percent had grade 3 nausea (0, grade 4),
and 15% had grade 3 vomiting (0, grade 4). Ten percent had
grade 3 anorexia (0, grade 4) and dehydration (0, grade 4), and
12% had grade 3 dyspnea (0, grade 4). Other nonhematologic
toxicities occurred in less than 10% of patients. Nonhematologic
toxicities specific to imatinib (rash, edema) were uncommon.
DISCUSSION
The tyrosine kinase KIT plays an important role in cell
development and growth regulation in some tumors. Ninety
FIGURE 4. Overall survival by KIT expres-
sion: positive or negative. pt, patient.
FIGURE 5. Progression-free survival (PFS)
by KIT expression: 0, 1, 2, 3. pt, pa-
tient.
FIGURE 6. Overall survival by KIT expres-
sion: 0, 1, 2, 3. pts. patients.
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percent of gastrointestinal stromal tumors express KIT in an
activated form because of a mutation in c-kit, the proto-
oncogene that encodes for the receptor.22 Several gain-of-
function mutations have been identified, involving exons 9,
11, 13, and 17, which account for this ligand-independent
receptor activation.23,24 Imatinib inhibits KIT and is associ-
ated with disease control in 80% of gastrointestinal stromal
tumors patients.9
KIT and its ligand, stem cell factor, are expressed in the
majority of SCLCs.25–30 This coexpression may lead to auto-
crine or paracrine activation and consequent cell proliferation.31
Recently, exon 9 and 11 mutations have been identified in a
subset of patients with SCLC,32 potentially explaining other
mechanisms for KIT activation in this disease.
Studies examining KIT’s value as a prognostic factor in
SCLC have been mixed.25,26 In a multivariate analysis of 203
SCLC patients, KIT expression was found to be an indepen-
dent prognostic factor, along with stage and performance
status. However, increased KIT expression was associated
with improved survival compared with decreased or no ex-
pression. Other retrospective analyses have found opposite
conclusions.33,34 Micke et al.33 examined tumor samples from
SCLC patients and correlated clinical outcomes with KIT
expression. In ES-SCLC patients who had only minor re-
sponses to chemotherapy and positive KIT expression, sur-
vival was shorter (median, 71 days; 95% CI:0–237) com-
pared with similar patients with KIT-negative tumors
(median, 288 days; 95% CI: 255–321; log rank test, p 
0.003). Additional support for targeting KIT comes from in
vitro studies in which Japanese investigators used antisense
adenovirus vectors expressing c-kit transcripts in KIT ex-
pressing SCLC cell lines. Infection of these cells resulted in
reduced KIT expression and cellular growth inhibition com-
pared to uninfected cells.35
The published experience with imatinib in the treatment
of SCLC has been limited. There have been three studies in
which imatinib has been used as a single agent,10–12 and more
recently, a phase I trial in which imatinib was combined with
chemotherapy36 (Table 5). Johnson et al.36 administered ima-
tinib to 19 patients, nine of whom had no previous treatment
and 10 with sensitive relapse. Four patients could not be
confirmed to have had SCLC with central review. There were
no objective responses; however, only four patients had
evidence of KIT expression. Similarly, two phase II studies
that required KIT expression for enrollment found no objec-
tive responses in patients with relapsed disease treated with
imatinib alone. Recently, phase I data were published on
previously untreated patients (n  9) with ES-SCLC who
received imatinib in combination with cisplatin and irinote-
can. KIT expression was identified in three of nine patients,
and five of six assessed patients responded.
The present study was designed to combine imatinib with
an active chemotherapy regimen. Several studies have found
TABLE 4. Grade 3/4 Treatment-Related Toxicity During
Irinotecan, Carboplatin, and Imatinib (n  68)
Patients
Toxicitya Grade 3, No. (%) Grade 4, No. (%)
Hematologic
Neutropenia 19 (28) 10 (15)
Thrombocytopenia 6 (9) 0
Anemia 9 (13) 2 (3)
Febrile neutropenia 4 (6) 1 (1)
Platelet transfusion 1 (1)
RBC transfusion 16 (24)
Nonhematologic
Anorexia 7 (10) 0
Atrial fibrillation 2 (3) 0
Dehydration 7 (10) 0
Diarrhea 13 (19) 0
Dyspnea 8 (12) 0
Edema 2 (3) 0
Fatigue/weakness 16 (24) 0
Hypokalemia 6 (9) 2 (3)
Infection 3 (4) 0
Nausea 18 (26) 0
Vomiting 10 (15) 0
Weight loss 2 (3) 0
RBC, red blood cell.
a Grade 3 and 4 toxicities occurring in 3% of patients.
TABLE 5. Published ES-SCLC Studies With Imatinib
Study No. Setting ORR
Median Time to
progression KIT Expression Comments
Johnson et al.11 19 No previous therapy, 9
Sensitive relapse, 10
0
0, 1 patient (KIT
negative) had SD
for 4.1 mo
0.8 mo
1.2 mo
21% (4 patients) SCLC not confirmed
in 5 patients
Dy et al.10 29 Sensitive relapse, 22
Refractory relapse, 7
0
0
1 mo
1.1 mo
100% (required
for enrollment)
Krug et al.12 12 Sensitive relapse, 6
Refractory relapse, 6
0
0
All with PD
by 4 wk
100% (required for
enrollment)
Johnson et al.36 9 No previous therapy. Imatinib
administered with cisplatin/irinotecan
83% (5 of 6 assessable
for response)
All with PD
by 3–5 mo
33% (3 of 9
assessed)
Information on KIT
status in responders
not available
ORR, objective response rate; SD, stable disease.
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irinotecan and carboplatin to be an active and well-tolerated
regimen in SCLC, with response rates of approximately
70%.13–15 In our multicenter phase II trial, treatment with irino-
tecan, carboplatin, and imatinib was found to be safe and
generally well tolerated, with an objective response rate of 66%
and a disease control rate (objective response rate  stable
disease) of 78%. Neutropenia, nausea, fatigue, and diarrhea were
significant toxicities; however, grade 4 toxicity was rare. Fifty-
six specimens (82%) were available for KIT analysis and 86%
of these had 1 or higher expression by immunohistochemical
scoring. KIT expression did not appear to correlate with im-
proved PFS or OS, although few KIT-negative patients (n  8,
14%) were available for comparison. Compared with historical
outcomes for first-line treatment of ES-SCLC with platinum-
based chemotherapy alone, the addition of imatinib does not
appear to offer any advantage.
This study is limited by its nonrandomized design and
small subsets for KIT expression to adequately assess KIT’s
value as a predictive marker. Additionally, this trial design
cannot readily distinguish the effects of imatinib from those
of combination chemotherapy.
Despite these limitations, these results do not support
further investigation of imatinib in SCLC. KIT expression does
not appear to be a valid target for drug development in SCLC.
Unlike in gastrointestinal stromal tumors in which activating
mutations account for constitutive receptor activity and conse-
quent tumor growth, KIT expression in SCLC may be more
reflective of downstream, rather than upstream, signaling. Iden-
tifying other targets, such as the vascular endothelial growth
factor, the insulin-like growth factor-I receptor, and the mam-
malian target of rapamycin kinase may prove to be more suc-
cessful strategies in improving SCLC treatment.
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